心脏衰竭中的表观遗传学
Jamie Sin Ying Ho1, Eric Jou2,3, Pek-Lan Khong4,5
1Department of Cardiology, National University Heart Centre, Singapore 119228, Singapore.
International journal of molecular sciences
|November 27, 2024
概括
诸如DNA甲基化和基因组变化的表观遗传修饰在心力衰竭的发展中起着关键作用. 对表观遗传疗法的研究为新的心力衰竭治疗和生物标志物提供了潜力.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 心力衰竭是一个日益严重的全球健康问题,预后不佳.
- 人们越来越认识到表观遗传修饰是病态心脏重塑的关键驱动因素.
- 压力激活的信号级联和表观遗传信号调节了心力衰竭中的基因表达.
研究的目的:
- 审查目前关于表观遗传修饰在心力衰竭中的作用的证据.
- 总结表观遗传疗法对心力衰竭的潜力.
- 突出进一步研究表观遗传学和心力衰竭治疗方法的需要.
主要方法:
- 关于表观遗传学和心力衰竭的现有科学文献的综述.
- 对DNA甲基化和各种基因组修饰的分析 (乙化,酸化,无化,化).
- 目前正在进行的表观遗传疗法开发和临床试验的总结.
主要成果:
- 表观遗传过程,包括DNA甲基化和基因组修饰,对于将环境压力转化为遗传表达至关重要,从而导致心脏重塑.
- 几种表观遗传修饰与心力衰竭的病理生理学有关.
- 目前,对于心力衰竭的表观遗传疗法的有限的临床试验已经可用.
结论:
- 表观遗传修饰是心力衰竭的发展和进展的组成部分.
- 表观遗传疗法对心力衰竭的新疗法,生物标志物和个性化医疗方法具有前景.
- 进一步阐明心力衰竭中的动态表观基因组变化对于治疗进步至关重要.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Human Genetics
535
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
535
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316


